Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 1
1978 2
1979 2
1981 5
1982 4
1983 5
1984 7
1985 14
1986 19
1987 13
1988 16
1989 23
1990 18
1991 28
1992 30
1993 27
1994 39
1995 45
1996 36
1997 57
1998 44
1999 51
2000 46
2001 59
2002 55
2003 70
2004 65
2005 65
2006 67
2007 68
2008 70
2009 86
2010 86
2011 88
2012 97
2013 107
2014 92
2015 103
2016 113
2017 105
2018 90
2019 122
2020 123
2021 119
2022 109
2023 102
2024 46

Text availability

Article attribute

Article type

Publication date

Search Results

2,374 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Limited Stage Lung Small Cell Carcinoma"
Page 1
Radiation and Systemic Therapy for Limited-Stage Small-Cell Lung Cancer.
Bogart JA, Waqar SN, Mix MD. Bogart JA, et al. J Clin Oncol. 2022 Feb 20;40(6):661-670. doi: 10.1200/JCO.21.01639. Epub 2022 Jan 5. J Clin Oncol. 2022. PMID: 34985935 Free PMC article. Review.
Progress in the overall treatment of small-cell lung cancer (SCLC) has moved at a slower pace than non-small-cell lung cancer. ...The addition of immunotherapy has resulted in mixed success in extensive-stage SCLC with modest benef …
Progress in the overall treatment of small-cell lung cancer (SCLC) has moved at a slower pace than non-small- …
Emerging Strategies for the Treatment of Small Cell Lung Cancer: A Review.
Petty WJ, Paz-Ares L. Petty WJ, et al. JAMA Oncol. 2023 Mar 1;9(3):419-429. doi: 10.1001/jamaoncol.2022.5631. JAMA Oncol. 2023. PMID: 36520421 Review.
IMPORTANCE: Small cell lung cancer (SCLC) is an aggressive disease that is characterized by rapid growth and the early development of metastases. ...Ongoing research has advanced the understanding of molecular categories and the immunologic microenvironment o …
IMPORTANCE: Small cell lung cancer (SCLC) is an aggressive disease that is characterized by rapid growth and the early …
DLL3: an emerging target in small cell lung cancer.
Owen DH, Giffin MJ, Bailis JM, Smit MD, Carbone DP, He K. Owen DH, et al. J Hematol Oncol. 2019 Jun 18;12(1):61. doi: 10.1186/s13045-019-0745-2. J Hematol Oncol. 2019. PMID: 31215500 Free PMC article. Review.
Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers. ...It is therefore being explored as a potential therapeutic target in SCLC. Here, we review the preclinical and clinical evidence for targeting DLL3 in SCLC and d …
Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers. ...It is therefore being explo …
Immunotherapy in Lung Cancer: Current Landscape and Future Directions.
Mamdani H, Matosevic S, Khalid AB, Durm G, Jalal SI. Mamdani H, et al. Front Immunol. 2022 Feb 9;13:823618. doi: 10.3389/fimmu.2022.823618. eCollection 2022. Front Immunol. 2022. PMID: 35222404 Free PMC article. Review.
Immune checkpoint inhibitors (ICIs) have shown tremendous benefit in the treatment of non-small cell lung cancer (NSCLC) and are now being used as first-line therapies in metastatic disease, consolidation therapy following chemoradiation in unresectable local …
Immune checkpoint inhibitors (ICIs) have shown tremendous benefit in the treatment of non-small cell lung cancer (NSCLC …
Radiation therapy for extensive-stage small-cell lung cancer in the era of immunotherapy.
Tian Y, Ma J, Jing X, Zhai X, Li Y, Guo Z, Yu J, Zhu H. Tian Y, et al. Cancer Lett. 2022 Aug 10;541:215719. doi: 10.1016/j.canlet.2022.215719. Epub 2022 May 18. Cancer Lett. 2022. PMID: 35597478 Review.
Unlike non-small-cell lung cancer (NSCLC), the progression of small-cell lung cancer (SCLC) is slow. ...In the era of chemotherapy, radiation therapy (RT), including thoracic radiation therapy (TRT) and brain radiation therapy (BRT), has …
Unlike non-small-cell lung cancer (NSCLC), the progression of small-cell lung cancer (SCLC) is slo …
Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer.
Park S, Noh JM, Choi YL, Chi SA, Kim K, Jung HA, Lee SH, Ahn JS, Ahn MJ, Sun JM. Park S, et al. Eur J Cancer. 2022 Jul;169:42-53. doi: 10.1016/j.ejca.2022.03.034. Epub 2022 Apr 29. Eur J Cancer. 2022. PMID: 35500460 Clinical Trial.
BACKGROUND: The current standard treatment for limited-stage small-cell lung cancer (LS-SCLC) is chemotherapy with concurrent chemoradiotherapy (CCRT). ...CONCLUSIONS: Durvalumab with CCRT for LS-SCLC exhibited promising clinical efficacy …
BACKGROUND: The current standard treatment for limited-stage small-cell lung cancer (LS-SCLC) is chemothe …
High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538.
Bogart J, Wang X, Masters G, Gao J, Komaki R, Gaspar LE, Heymach J, Bonner J, Kuzma C, Waqar S, Petty W, Stinchcombe TE, Bradley JD, Vokes E. Bogart J, et al. J Clin Oncol. 2023 May 1;41(13):2394-2402. doi: 10.1200/JCO.22.01359. Epub 2023 Jan 9. J Clin Oncol. 2023. PMID: 36623230 Free PMC article. Clinical Trial.
PURPOSE: Although level 1 evidence supports 45-Gy twice-daily radiotherapy as standard for limited-stage small-cell lung cancer, most patients receive higher-dose once-daily regimens in clinical practice. ...CONCLUSION: Although 45-Gy twi …
PURPOSE: Although level 1 evidence supports 45-Gy twice-daily radiotherapy as standard for limited-stage small-cell …
Radiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guideline.
Simone CB 2nd, Bogart JA, Cabrera AR, Daly ME, DeNunzio NJ, Detterbeck F, Faivre-Finn C, Gatschet N, Gore E, Jabbour SK, Kruser TJ, Schneider BJ, Slotman B, Turrisi A, Wu AJ, Zeng J, Rosenzweig KE. Simone CB 2nd, et al. Pract Radiat Oncol. 2020 May-Jun;10(3):158-173. doi: 10.1016/j.prro.2020.02.009. Epub 2020 Mar 23. Pract Radiat Oncol. 2020. PMID: 32222430 Free PMC article.
PURPOSE: Several sentinel phase III randomized trials have recently been published challenging traditional radiation therapy (RT) practices for small cell lung cancer (SCLC). This American Society for Radiation Oncology guideline reviews the evidence f …
PURPOSE: Several sentinel phase III randomized trials have recently been published challenging traditional radiation therapy (RT) pra …
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, Bezjak A, Cardenal F, Fournel P, Harden S, Le Pechoux C, McMenemin R, Mohammed N, O'Brien M, Pantarotto J, Surmont V, Van Meerbeeck JP, Woll PJ, Lorigan P, Blackhall F; CONVERT Study Team. Faivre-Finn C, et al. Lancet Oncol. 2017 Aug;18(8):1116-1125. doi: 10.1016/S1470-2045(17)30318-2. Epub 2017 Jun 20. Lancet Oncol. 2017. PMID: 28642008 Free PMC article. Clinical Trial.
BACKGROUND: Concurrent chemoradiotherapy is the standard of care in limited-stage small-cell lung cancer, but the optimal radiotherapy schedule and dose remains controversial. The aim of this study was to establish a standard chemoradiotherapy t …
BACKGROUND: Concurrent chemoradiotherapy is the standard of care in limited-stage small-cell lung cancer, …
High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial.
Grønberg BH, Killingberg KT, Fløtten Ø, Brustugun OT, Hornslien K, Madebo T, Langer SW, Schytte T, Nyman J, Risum S, Tsakonas G, Engleson J, Halvorsen TO. Grønberg BH, et al. Lancet Oncol. 2021 Mar;22(3):321-331. doi: 10.1016/S1470-2045(20)30742-7. Lancet Oncol. 2021. PMID: 33662285 Clinical Trial.
BACKGROUND: Concurrent chemoradiotherapy is standard treatment for limited stage small-cell lung cancer (SCLC). Twice-daily thoracic radiotherapy of 45 Gy in 30 fractions is considered to be the most effective schedule. ...Follow-up is ongoing. …
BACKGROUND: Concurrent chemoradiotherapy is standard treatment for limited stage small-cell lung cancer ( …
2,374 results